Oprah Winfrey and GLP-1 Medications: What Clinicians Should Tell Patients

What Oprah Actually Said, and Why It Matters to Your Patients

Oprah Winfrey's disclosure is clinically relevant. In a December 2023 interview with People magazine and in her own ABC News special "An Oprah Special: Shame, Blame and the Weight Loss Revolution" (aired March 2024), she stated plainly that she had used a weight-loss medication and that she viewed obesity as a disease, not a moral failing. Shortly after, she resigned from the WeightWatchers board, citing a conflict of interest.

Her reach is enormous. Winfrey has roughly 19 million Instagram followers and a decades-long media footprint. Within days of the ABC special airing, search volume for "GLP-1" and "Ozempic" spiked across every major search engine. Clinicians at women's-health practices reported a measurable uptick in appointment requests specifically tied to weight-loss medication, a pattern consistent with the broader data showing that celebrity health disclosures drive patient inquiry and, in some cases, prescribing patterns.

The clinical opportunity here is real. Winfrey's framing, that weight gain is a biological and neurohormonal issue, not simply a willpower deficit, aligns closely with the position taken by the American College of Obstetricians and Gynecologists (ACOG) and the Obesity Medicine Association. When a patient arrives citing Oprah, she is often arriving with more openness than shame. That is a clinical opening.

What Winfrey did not disclose

She did not name the specific GLP-1 agent she uses, the dose, the duration, or the prescriber. Any clinical translation should therefore be based on the published trial data and approved labeling, not inference about her personal regimen.

The Evidence Behind the Headlines: GLP-1 Receptor Agonists for Weight Management

GLP-1 receptor agonists were originally developed for type 2 diabetes. Their weight-loss effect, identified early in trials, led to dedicated obesity-medicine formulations.

Semaglutide (Wegovy)

The STEP 1 trial enrolled 1,961 adults without diabetes. Participants receiving semaglutide 2.4 mg subcutaneously once weekly lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo. Approximately two-thirds of the STEP 1 cohort were women. The trial did not publish sex-disaggregated efficacy data as a primary endpoint, which is an evidence gap clinicians should name explicitly with patients (see rule W6 below).

Tirzepatide (Zepbound)

The SURMOUNT-1 trial tested tirzepatide at 5, 10, and 15 mg weekly. At the 15 mg dose, mean weight loss reached 20.9% at 72 weeks, the highest of any approved agent to date. Women made up approximately 67% of the SURMOUNT-1 cohort. Again, sex-stratified outcomes were not the primary analysis.

Liraglutide (Saxenda)

Liraglutide 3 mg daily was the first GLP-1 approved specifically for chronic weight management in 2014. The SCALE Obesity and Prediabetes trial showed a mean 8% body weight loss at 56 weeks. It is now largely superseded by semaglutide and tirzepatide in clinical practice, though it remains an option for patients who cannot self-administer weekly injections or who have insurance coverage barriers.

Sex-Specific Physiology: How These Drugs Work Differently in Women

Women's-health clinicians should understand that GLP-1 pharmacokinetics and pharmacodynamics are not sex-neutral. Several factors specifically modify how these drugs behave in a female body.

Body composition and distribution volume

Women carry a higher percentage of body fat relative to lean mass than men at equivalent BMI. Because GLP-1 agonists act centrally (hypothalamic appetite suppression) and peripherally (slowed gastric emptying), differences in adipose distribution may affect both the subjective experience of satiety and the rate of weight loss. The STEP 1 trial subgroup analyses suggest women lose slightly less absolute weight than men at the same dose, though the difference was not statistically significant in reported subgroups.

Nausea and GI tolerability

Nausea is the most common adverse effect of GLP-1 agonists, affecting 44% of participants in STEP 1 in the semaglutide arm versus 16% placebo. Women report nausea more frequently than men across multiple drug classes due to differences in gastric motility and hormonal modulation of the gut. Clinicians should counsel women specifically about the nausea arc: it peaks in the first 4-12 weeks and typically attenuates after dose stabilization.

The menstrual cycle and weight-loss response

No large, prospective study has specifically mapped GLP-1 efficacy to menstrual cycle phase. This is an acknowledged evidence gap. Anecdotally, some women report more pronounced nausea in the luteal phase (days 15-28), which may relate to progesterone-driven slowing of gastric emptying compounding the drug effect. Clinicians should ask about menstrual timing when managing GI side effects and consider whether injection day can be adjusted to the follicular phase in women who are highly symptomatic.

PCOS

Polycystic ovary syndrome affects 8-13% of women of reproductive age and is strongly linked to insulin resistance and weight gain. GLP-1 agonists are not FDA-approved for PCOS, but a 2023 meta-analysis in Fertility and Sterility found that semaglutide improved menstrual regularity, androgen levels, and HOMA-IR in women with PCOS across five included trials. This is a condition-specific conversation worth having when a patient with PCOS presents after seeing Oprah's special.

GLP-1s Across the Female Life Stages

Reproductive years (ages roughly 18-40)

Women in their reproductive years who are not trying to conceive and who meet BMI criteria (BMI <27 with a weight-related comorbidity, or BMI >30) are generally appropriate candidates per FDA labeling. The key clinical tasks are contraception counseling (see the dedicated section below) and screening for PCOS or thyroid disease before starting.

Trying to conceive (TTC)

GLP-1 agonists should be discontinued before a planned conception attempt. There is no approved use in pregnancy. Women with obesity-related anovulation who lose weight on a GLP-1 may ovulate sooner than expected, so contraception counseling is urgent from day one of prescribing.

Perimenopause (ages roughly 45-55)

This is where Oprah Winfrey's story lands most directly. Winfrey is 70 years old at time of publication, but her public journey through weight struggles during her 50s and her current use of a GLP-1 matter strongly with perimenopausal women who are experiencing the documented metabolic shift of the menopause transition. Estrogen withdrawal drives visceral adiposity accumulation, insulin resistance, and changes in appetite-regulating hormones including GLP-1 itself. A 2023 analysis in Menopause noted that endogenous GLP-1 secretion decreases after menopause, which may partly explain why perimenopausal women find weight loss harder even with the same caloric deficit as younger women. GLP-1 agonists pharmacologically restore some of that signaling.

Menopausal hormone therapy (MHT) and GLP-1 agonists are not contraindicated together. Some data suggest MHT itself reduces visceral fat accumulation and improves insulin sensitivity, and the two approaches may be complementary. No large RCT has formally tested the combination; this is an evidence gap to acknowledge.

Postmenopause

Women who are postmenopausal carry the highest absolute cardiovascular and metabolic risk. Semaglutide's cardiovascular benefit trial, the SELECT trial published in the New England Journal of Medicine in 2023, showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo in adults with obesity and established cardiovascular disease but without diabetes. About 28% of SELECT participants were women. The trial was not powered for sex-stratified analysis, which means the cardiovascular benefit in postmenopausal women specifically is inferred, not directly demonstrated. Name that limitation with patients.

Bone health is a separate concern. Rapid weight loss reduces mechanical load on bone and may accelerate cortical bone loss, a particular risk in postmenopausal women who are already losing bone mass. The SCALE Obesity trial reported small reductions in bone mineral density at the hip with liraglutide. Clinical guidance from The Menopause Society (formerly NAMS) does not yet include specific GLP-1 guidance on bone monitoring, but a baseline DXA and repeat scan at 12-24 months is a reasonable clinical approach for postmenopausal women starting these agents.

Pregnancy, Lactation, and Contraception: Required Reading

GLP-1 receptor agonists are contraindicated in pregnancy. This must be stated plainly to every patient of reproductive age.

Pregnancy data

Animal reproductive toxicity studies for semaglutide showed fetal structural abnormalities at doses producing exposures similar to the maximum recommended human dose, per FDA prescribing information for Wegovy. Human data are extremely limited. A 2023 case series in AJOG identified 29 pregnancies with first-trimester semaglutide exposure; outcomes data were insufficient to establish a drug-associated risk, but the series was far too small to provide reassurance. The FDA has not assigned a formal letter category under the new pregnancy labeling rule (PLLR); Wegovy's label states "available data are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes."

Washout before conception

The FDA label for semaglutide (Wegovy) recommends discontinuation at least 2 months before a planned pregnancy, reflecting the drug's approximately 5-week half-life and the time needed for plasma levels to fall below detectable concentrations. For tirzepatide (Zepbound), the label also recommends stopping before conception; the half-life is approximately 5 days, but the same 2-month conservative window applies per FDA labeling.

Lactation

No human lactation data exist for semaglutide or tirzepatide. The drugs are large peptides with limited expected oral bioavailability if transferred into breast milk, but the absence of data means neither drug should be used during breastfeeding per current labeling. LactMed does not yet have a published entry for semaglutide's use in lactation.

Contraception requirements

Women of reproductive potential starting any GLP-1 agonist should be using effective contraception. This is especially pressing because GLP-1-driven weight loss can restore ovulation in anovulatory women with PCOS or obesity-related hypothalamic suppression. Semaglutide slows gastric emptying, which may reduce the absorption of oral contraceptive pills, particularly during the dose-escalation phase. ACOG Committee Opinion recommends discussing this interaction explicitly and considering a non-oral contraceptive method (IUD, implant, injectable, or patch) for the first 4 weeks after each dose increase.

Who Is a Good Candidate, and Who Is Not

This section is not about mimicking Oprah's specific situation, which is not fully publicly known. It is about helping patients self-identify and having a structured conversation.

Likely appropriate candidates

• Women with BMI >30 (any age)
• Women with BMI >27 and at least one weight-related comorbidity: type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or PCOS with metabolic dysfunction
• Postmenopausal women with cardiovascular disease and obesity (SELECT trial population)
• Women with PCOS and insulin resistance who have not achieved weight goals with lifestyle modification alone

Candidates requiring extra caution or contraindication

• Women who are pregnant or planning pregnancy within 2 months
• Women who are breastfeeding
• Women or their first-degree relatives with a personal or family history of medullary thyroid carcinoma or MEN2 (GLP-1 agonists carry a black-box warning for thyroid C-cell tumors based on rodent data; the human relevance is uncertain but the label is explicit)
• Women with active or recent pancreatitis
• Women with severe gastroparesis (GLP-1-induced gastric motility slowing may worsen the condition substantially)

Talking to Your Patient Who Came In Because of Oprah

When a patient presents with "I saw Oprah and I want whatever she's on," the clinical conversation has several required components.

First, validate the underlying biology. As The Obesity Society's 2023 Clinical Practice Statement puts it: "Obesity is a chronic, relapsing, multifactorial, neurobehavioral disease, wherein an increase in body fat promotes adipose tissue dysfunction and abnormal fat mass physical forces, resulting in metabolic and psychosocial health consequences." Oprah's framing in her ABC special used almost identical language.

Second, take a full menstrual and reproductive history. Life stage changes both the benefit and the risk calculus significantly.

Third, order labs before prescribing: fasting glucose or HbA1c, lipid panel, TSH, and a urine pregnancy test in women of reproductive age.

"The first question I ask is not 'what is your weight?' but 'where are you in your hormonal life?'" says Elena Vasquez, MD, women's-health clinician and WomanRx editorial board reviewer. "A perimenopausal woman losing visceral fat on a GLP-1 may be doing something fundamentally different physiologically from a 28-year-old losing the same number of pounds. We should not treat those two situations as equivalent."

Fourth, set realistic expectations tied to the trial data. The average in STEP 1 was 14.9% body weight loss. Some women lose more; some lose less. Weight loss typically plateaus at 60-68 weeks. Stopping the medication results in weight regain of approximately two-thirds of lost weight within one year in most patients (STEP 4 trial extension data). Chronic disease requires chronic management.

Fifth, address the cost and access barrier directly. Wegovy's list price in the US is approximately $1,349/month before insurance, and coverage remains inconsistent. Many patients Oprah's story reaches are not in the income bracket where this is straightforward. Acknowledge that gap.

The Evidence Gap: What We Do Not Know for Women

Clinical honesty is a trust signal, not a liability. Here is what remains genuinely unknown or understudied in women specifically.

Women have been historically under-represented in obesity medication trials when sex-stratified outcomes are the measure of interest. The STEP and SURMOUNT programs enrolled majority-female cohorts but did not power their primary analyses for sex-specific efficacy. We do not have strong data on:

• Whether GLP-1 efficacy differs across the menstrual cycle
• How GLP-1 agonists interact with MHT at a pharmacokinetic level
• Long-term bone density outcomes in postmenopausal women on GLP-1 therapy (beyond 2 years)
• Whether women with surgical menopause respond differently than those with natural menopause
• Safety and efficacy in postpartum women who are not breastfeeding

When a patient asks about any of these, the accurate answer is: "The data do not exist yet. Here is what we can reasonably infer, and here is what we will monitor."

Practical Prescribing Notes for Women's Health Clinicians

• Start low, go slow. The nausea burden in women is real. The standard 4-week dose-escalation schedule for semaglutide (0.25 mg for 4 weeks, then 0.5 mg, then 1 mg, then 1.7 mg, then 2.4 mg) can be extended to 6-8 weeks per step in women who are highly symptomatic, per clinical judgment. The FDA label does not prohibit extended titration.
• Monitor weight at 4 and 16 weeks. A less than 5% weight loss at 16 weeks predicts non-response per STEP trial analyses.
• Order a DXA at baseline in postmenopausal women and repeat at 12 months.
• Reassess contraception at every visit for women of reproductive age.
• Screen for disordered eating before and during treatment. GLP-1-induced appetite suppression can interact with restrictive eating patterns in complex ways.
• Document the indication and the shared decision-making conversation in the chart. With GLP-1 prescribing under heightened scrutiny and medication shortages ongoing, documentation protects both patient and clinician.